Identifying Risk of Viral Failure in Treated HIV-Infected Patients Using Different Measures of Adherence: The Antiretroviral Therapy Cohort Collaboration

Journal of Clinical Medicine

Viviane D. Lima¹  Benita Yip¹  Heidi M. Crane²  Michael J. Mugavero³  M John Gill⁴  Jodie Guest⁵  Adriana Ammassari⁶  Margaret T. May⁷  Suzanne M. Ingle⁷  Jonathan A. C. Sterne⁷  Nicholas L. Turner⁷  Nikola Hanhoff⁸  Tracy R. Glass⁹  Jan P. Tate^1,10 

[1] British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC V6Z 1Y6, Canada;Clinical Epidemiology and Health Services Research Core, Center for AIDS Research, University of Washington, WA 98104, USA;Division of Infectious Disease, Department of Medicine, University of Alabama, Birmingham, AL 35294, USA;Division of Infectious Diseases, University of Calgary, Calgary, AB T2N 4N1, Canada;HIV Atlanta VA Cohort Study (HAVACS), Rollins School of Public Health at Emory University, Atlanta, GA 30322, USA;Istituto Nazionale Malattie Infettive “L. Spallanzani”, IRCCS, 00149 Rome, Italy;Population Health Sciences, Bristol Medical School, University of Bristol, Bristol BS8 2PS, UK;Southern Alberta Clinic, Calgary, AB T2R 0X7, Canada;Swiss Tropical and Public Health Institute, CH-4002 Basel, Switzerland;Yale University School of Medicine, West Haven, CT 06510, USA;

关键词: HIV;    antiretroviral therapy;    adherence;    viral failure;    cohort studies;   

DOI  :  10.3390/jcm7100328

来源: DOAJ

【 摘 要 】

Adherence to antiretroviral therapy (ART) is critical for successful treatment of Human Immunodeficiency Virus (HIV), but comparisons across settings are difficult because adherence is measured in different ways. We examined utility of different adherence measures for identification of patients at risk of viral failure (VF). Eight cohorts in the ART Cohort Collaboration contributed data from pharmacy refills or self-report questionnaires collected between 1996 and 2013 (N = 11689). For pharmacy data (N = 7156), we examined associations of percentage adherence during the 1st year of ART with VF (>500 copies/mL) at 1 year. For self-report data (N = 4533), we examined 28-day adherence with VF based on closest viral load measure within 6 months after questionnaire date. Since adherence differed markedly by measurement type, we defined different cut-off points for pharmacy (lower <45%, medium 45–99%, higher 100%) and self-report (lower ≤95%, medium 96–99%, higher 100%) data. Adjusted odds ratios (ORs) for VF in lower and medium, compared to higher adherence groups, were 23.04 (95% CI: 18.44–28.78) and 3.84 (3.36–4.39) for pharmacy data. For self-report data, they were 3.19 (2.31–4.40) and 1.08 (0.80–1.46). Both types of measure were strongly associated with VF. Although adherence measurements over longer time-frames are preferable for prediction, they are less useful for intervention.

【 授权许可】

Unknown